Role of Glycosuria in SGLT2 Inhibitor-Induced Cardiorenal Protection: A Mechanistic Analysis of the CREDENCE Trial.

"Duality of Interest. E.F. received a research grant for this study from Janssen, has received research grants from Boehringer-Ingelheim, and has received consultancy or speaker fees from Sanofi, Bohringer Ingelheim, and Lilly & Co. D.P. and M.K.H. are full-time employees of Janssen Research & Development, LLC. No other potential conflicts of interest relevant to this article were reported."

"CREDENCE was sponsored by Janssen Research and Development, LLC, and was conducted as a collaboration between the sponsor, an academic steering committee, and an academic research organization, George Clinical. Canagliflozin was developed by Janssen Research & Development, LLC, in collaboration with Mitsubishi Tanabe Pharma Corporation."

"Details of the trial design and oversight, participants, inclusion and exclusion criteria, randomization, treatment, follow-up, and outcomes have been published () (the CREDENCE trial is registered with ClinicalTrials.gov [identifier NCT02065791]). CREDENCE was stopped early after a planned interim analysis, with a final median follow-up of 2.6 years."